RLRichard Lobo

Richard Lobo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Richard Lobo has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advanced Recovery Strategies for Herbal Bioactives from Pharmaceutical Nanoformulations: A Narrative Review

    by Manoj Madanahalli Ramesh, Richard Lobo, Annegowda Hardur Venkatappa

  • Top Cited Papers

    Pharmacological Complexities of Herbal Medicinal Extracts: A Review of Bioavailability, Interactions, and Standardization

    by Manoj Madanahalli Ramesh, Sneha Dinesh, Annegowda Hardur Venkatappa, Richard Lobo

    Herbal medicines have gained remarkable popularity due to their natural origins and potential medicinal value. Nevertheless, they are chemically complex and pose signifi-cant pharmacological challenges. This review focuses on the key aspects influencing their clinical use: their variable bioavailability, complex pharmacokinetics (ADME), and potential for interactions. A primary concern is herb-drug interactions, with special emphasis on the modulation of drug-metabolizing enzymes by specific phytoconstituents, which can alter drug concentrations to an extent that may be life-threatening, causing either increased toxicity or therapeutic failure. The pharmacological profile is further complicated by the complex effects of constituents, such as synergistic or antagonistic actions, which make predicting therapeutic response and safety difficult. A critical challenge in this field is the frequent dis-connect between in vitro findings and in vivo outcomes, underscoring the importance of phar-macokinetic data, particularly bioavailability, for accurate clinical risk assessment. Safety is a paramount concern, as it is often compromised by inconsistent standardization and quality control, leading to batch-to-batch variability, potential adulteration, and contamination. The absence of stringent regulation impairs therapeutic consistency and introduces health risks. To address these issues, advanced approaches are being employed to improve bioavailability, including novel drug delivery systems that enhance solubility and stability. This review em-phasizes that a rigorous, phytoconstituent-centric approach is essential for navigating the complexities of herbal medicine. By addressing challenges in pharmacokinetics, interactions, safety, standardization, and bioavailability through rigorous scientific investigation and em-bracing future perspectives, such as in silico modeling and improved regulatory frameworks, the quality, safety, and effectiveness of herbal treatments can be ensured, supporting their responsible integration into modern, evidence-based medical systems.


  • Exploring The Multifaceted Medicinal Benefits of Phyllanthus niruri: Insights into Its Antiurolithic, Hepatoprotective and Anti-Diabetic Activities

    by Vijishna Lekshmi Viswambharan, Praveen Halagali, Raagul Seenivasan, Vamshi Krishna Tippavajhala, Richard Lobo

    : Phyllanthus niruri L., (p. niruri) commonly known as the 'Stone breaker plant', has been widely used worldwide as a typical remedy of nature for a long time, for the treatment of kidney health and urinary diseases mainly. According to the given ethnomedicine and traditional uses of the herb, it can have various therapeutic applications for classes of human diseases. This exhaustive review first of all concentrates on the food values, phytochemical profile, antidiabetic, antiurolithic, hepatoprotective activities, and formulation studies, and also checks the safety, toxicity, and clinical trials of P. niruri. P. niruri has yielded a total of 120 phytoconstituents. The major biologically active compounds identified are alkaloids, tannins, coumarins, sterols, phenolic acid, flavonoids, and lignans. These compounds are the major reason for the huge pharmacological activities of the plant, which comprise antiviral, immunomodulatory, hepatoprotective, antidiabetic, antiurolithic, anti-inflammatory, antibacterial, anticancer, antifungal, and tranquilizing effects. P. niruri highlights a wonderful perspective, especially with its antidiabetic, antiurolithic, and hepatoprotective properties, showing its potential application in future therapy regimens. In multiple clinical trials, P. niruri remains a treatment option of great value for patients irrespective of their ages, and additionally, it is a safe and efficacious alternative.

  • Open Access

    Pharmacological enhancement of anti-inflammatory drug efficacy through solid lipid nanoparticles in osteoarthritis and rheumatoid arthritis: a review

    by Manoj Madanahalli Ramesh, Richard Lobo, Annegowda Hardur Venkatappa

    Chronic inflammatory diseases, such as rheumatoid arthritis and osteoarthritis, are sustained by dysregulated cytokine signaling, eicosanoid production, and the continuous activation of intracellular inflammatory pathways. Although nonsteroidal anti-inflammatory drugs, corticosteroids, and disease-modifying drugs are foundational treatments, their long-term use is limited due to unfavorable pharmacokinetics, lack of tissue selectivity, and systemic side effects. Solid lipid nanoparticles (SLNs) have emerged as a promising delivery system. They serve as lipid carriers, enabling better control of drug distribution while preserving pharmacodynamic effects. Preclinical studies indicate that SLN formulations can enhance the pharmacokinetics of anti-inflammatory drugs by promoting local retention, providing extended release, and increasing local drug exposure at sites of inflammation following topical, intra-articular, or systemic administration. At the molecular level, drugs delivered using SLNs consistently inhibit key inflammatory mediators, including TNF-α, IL-1β, IL-6, and PGE₂. These actions are associated with reduced activation of nuclear factor-κB and Janus kinase/signal transducer and activator of transcription pathways, as well as decreased oxidative stress and leukocyte accumulation in inflamed joints and surrounding tissues. Importantly, SLNs do not change the inherent action of the drugs they carry; instead, they enhance their pharmacological effectiveness by prolonging drug concentration at the target site and reducing exposure to non-target tissues. This fine-tuning of pharmacokinetics can lead to dose-saving strategies, which are particularly vital in the long-term management of arthritis. SLNs are an active delivery system that improves the performance of anti-inflammatory drugs by modulating controlled exposure and altering molecular pathways. However, further prolonged dosing studies and clinical trials are necessary to fully establish their clinical utility. Graphical abstract


  • Open Access

    Sesbania grandiflora (L.) Pers.: A review of its phytochemistry, molecular pharmacology, and clinical potential

    by Vijishna Lekshmi Viswambharan, Manoj Madanahalli Ramesh, Rudresh Adarkar, Maria Nison, Megha Kotian, Vasudev R. Pai, Chandrashekhar K. S. Bhat, Richard Lobo

    Sesbania grandiflora (L.) Pers. is a valuable medicinal herb with numerous traditional uses, yet its contribution to an evidence-based therapeutic potential is incomplete. This comprehensive review focuses on the current state of knowledge, the mechanistic analysis of its activities, pharmacokinetics, pharmacodynamics, and clinical validation. It also reveals a rich phytochemical profile of compounds such as isoflavonoids (medicarpin), triterpenes (betulinic acid), and unique 2-arylbenzofurans with significant anti-tubercular activity. Mechanistic studies validate its anticancer activity modulating PI3K/Akt signalling pathways and the induction of mitochondrial-mediated apoptosis. Its apoptotic activity is linked to the inhibition of key carbohydrate-metabolizing enzymes. However, clinical translation is impeded by significant challenges, including the poor bioavailability of key lipophilic compounds, genotoxicity, and safety concerns. Still, robust clinical trial evidence provided that the first randomized controlled trial evaluated a standardized extract in improving heart health. In conclusion, while S. grandiflora confirms the confirmatory potential, its future as a modern botanical medicine depends on systematically managing the identified gaps in pharmacokinetics and long-term safety to develop standardized and efficacious formulations.

  • Open Access

    Computational design, synthesis, in vitro and in vivo evaluation of a 3,4-methylenedioxyphenol (sesamol) derivative as an NRF2/HO-1 pathway activator for protection against drug-induced liver injury

    by Ajay Mili, Sumit Birangal, Krishnadas Nandakumar, Raghu Chandrashekar Hariharapura, Nitesh Kumar, Aravinda Pai, Richard Lobo

    A sesamol derivative (SMD) was designed as a potent NRF2/HO-1 activator showing enhanced hepatoprotection in vitro and in vivo .

  • Open Access

    Solvent-driven stability: UV spectroscopy study of phenolic substances

    by Manoj Madanahalli Ramesh, Annegowda Hardur Venkatappa, Richard Lobo

    In contemporary industry, the analysis of various substances often requires handling samples with appropriate solvents, relying on stock solutions for research purposes. This study investigates the stability of gallic acid, ellagic acid, and quercetin naturally occurring polyphenolic compounds with potential pharmaceutical applications. The study explored the stability of these materials in different solvent environments and at varied temperatures, highlighting the critical role of solvent choice and temperature in preserving compound integrity. Gallic acid, quercetin, and ellagic acid were each dissolved at a concentration of 5 µg/mL in different solvents. UV spectroscopic analysis was conducted periodically over one month, with samples stored in controlled environments. Stability was assessed by examining UV absorption spectra, and data were analyzed using statistical methods. The results indicated that the choice of solvent significantly impacted compound stability. Gallic acid showed the highest stability in ethanol (100%) and DMSO (10%) at both room and refrigerated temperatures. Ellagic acid demonstrated optimal stability in DMSO (10%), with variability in other solvents. Quercetin exhibited the highest stability in DMSO (10%), while ethanol showed significant variability. Refrigeration enhanced stability across all solvents. These findings underscore the importance of selecting appropriate solvents and storage conditions to preserve the quality of active pharmaceutical ingredients (API). The results offer valuable insights for improving the stability of stock solutions in pharmaceutical development and quality control, providing crucial information for enhancing the preservation of APIs.

  • Open Access

    THE ANTIOSTEOPOROTIC POTENTIAL OF HESPERIDIN AND ADVANCED DELIVERY SYSTEMS

    by Vijishna L. V., Akanksha D. Dessai, Usha Y. Nayak, Richard Lobo

    This study explores Hesperidin (HP) and its bone-protective effect against Osteoporosis (OP), summarizing its healing mechanisms supported by in vitro and in vivo evidence and insights into its ethnobotanical significance and advanced drug delivery systems. To gather information on the antiosteoporotic potential of HP, we thoroughly searched many scientific databases, including Science Direct, Google Scholar, PubMed, and Scopus, for articles published between 1990 and 2025. Data were collected using the keywords HP, traditional uses, phytochemistry, anti-OP, and drug delivery systems. Only studies published in English are considered for this review. It has gained attention for potential health benefits, especially the osteoprotective effect. In vitro studies found that HP reverses dexamethasone-induced inhibition of osteogenic differentiation by suppressing the p53 (Protein 53) pathway. In rat models of Postmenopausal (PM), senile, and disuse OP, HP showed bone-protective benefits. Clinical trials revealed a 15% increase in serum calcium and a 25% increase in osteocalcin levels, indicating enhanced bone formation. Comparative analysis showed that HP's efficacy in increasing bone mineral density is similar to that of bisphosphonates. The findings demonstrate that HP is an excellent therapeutic candidate that protects the skeleton through various mechanisms. Future research should focus on developing HP-based nutraceuticals or pharmaceuticals, integrating traditional knowledge with modern pharmacological approaches to enhance bone health. Despite its potential, the efficacy of HP formulations in treating OP has not yet been investigated.

  • Open Access

    Identification of phytomolecules as isoform and mutation specific PI3K-α inhibitor for protection against breast cancer using e-pharmacophore modeling and molecular dynamics simulations

    by Ajay Mili, Sumit Birangal, Jyothi Giridhar, Krishnadas Nandakumar, Richard Lobo

    PI3K-α mutation plays a critical role in cancer development, notably in breast cancer, particularly within HR + /HER2- subtypes. These mutations drive tumor growth and survival by activating the PI3K/AKT/mTOR pathway, which is essential for cell proliferation and survival. Our research aimed to identify natural compounds that can inhibit mutant and specific isoforms of PI3K-α to prevent tumor progression. e-Pharmacophore model was generated using Receptor-Ligand complex using the Inavolisib drug (PDB:8EXV) and phase screening was performed using the Molport database of natural compounds. Through molecular docking studies we identified seven promising compounds for further molecular dynamics simulations. Among these, three compounds—STOCK1N-85097, STOCK1N-85998, and STOCK1N-86060—showed significant stability and interaction with PI3K-α. These compounds demonstrated favorable results in several parameters, including RMSD, RMSF, Rg, SASA, PCA, FEL, and total energy evaluations. Therefore, these compounds are projected to function as PI3K-α inhibitors and because of its natural origin it can possess fewer side effects than the conventional medicine, which should be validated by proper in vivo and in vitro models. Graphical Abstract


  • Open Access

    Efficacy of Lycium barbarum (Goji berry) mouthwash for managing periodontitis: a randomized clinical trial

    by Amee Sanghavi, Laasya Shettigar, Aditi Chopra, Ashmeet Shah, Richard Lobo, Padmaja A Shenoy, ShivaPrasada Gadag, Usha Y Nayak, Mangalore Shravya S, Shobha Ullas Kamath, et al.

    Background Removal of the microbial deposits (plaque and calculus) by performing effective scaling and root planing (SRP) is the fundamental step for managing periodontal disease (gingivitis and periodontitis). Various adjuncts in the form of mouthwash, gels, and toothpaste are also being used as adjuncts to SRP for managing periodontitis. Recently, Lycium barbarum (L. barbarum), commonly known as goji berry or wolfberry, has gained popularity for managing chronic inflammatory and infectious diseases. However, its efficacy in managing periodontitis has never been explored. Hence the present study aims to evaluate the efficacy of goji berry mouthwash compared to chlorhexidine mouthwash for managing periodontitis. Methods 60 adult participants were divided randomly using computer-generated random sequences into two groups (case group: L. barbarum mouthwash (Males: 16; Female: 14); control group: 0.2% chlorhexidine gluconate mouthwash (Males: 14; Females: 16)). The changes in the gingival index (Gi), plaque index (Pi), bleeding on probing (BOP), clinical attachment loss (CAL), probing pocket depth (PPD), microbial load, and antioxidant levels (protein thiol) in saliva were noted at the baseline, at 15 days and one month. Results A significant reduction in the mean PPD, Pi, BOP, and Gi was seen from baseline to one month in both the control (P-value=0.006, 0.027, 0.000, and 0.036 respectively) and test groups (P-value=0.035, 0.000, 0.034, and 0.000 respectively). However, the antioxidant levels (protein thiol) in saliva were significantly increased only in the test group. Conclusion Goji berry mouthwash along with SRP reduced the Gi, Pi, BOP, and PPD in patients with periodontitis. However, no statistically significant difference was noted between the use of goji berry and chlorhexidine mouthwash. Goji berry mouthwash was more effective than chlorhexidine in increasing the antioxidant levels in saliva.